2022 Poster Presentations Coming in October


2021 Poster Presentations:

P01: Human mAbs Combatting All Common Variants of SARS-CoV-2, Presented by Jos R., AbSano BV

P02: Plasma B Cell Screening Balances “High-Content” and “High Resolution” for Antibody Discovery, Presented by Ryan K., Abveris

P03: Surface Plasmon Resonance Microscopy: Label-Free Binding Kinetics of Membrane Proteins on Cell Surface, Presented by Akemi U., Biosensing Instrument

P04: A Recombinant SARS-CoV-2 Neutralizing Antibody Blocks The Spike RBD-ACE2 Interaction: A Biophysical Characterization Using SPR, Presented by Zahra A., Cayman Chemical Company

P05: High-Throughput Assessment of Cardiac Safety via Contractility Measurements of 3D Engineered Heart Tissues Using a Novel Instrumentation Platform, Presented by Nicholas G., Curi Bio

P06: Quantify Diverse Immune Cell-Mediated Killing Mechanisms: Applications of a Robust, Non-Radioactive KILR Cytotoxicity Platform, Presented by Gaurav A., Eurofins DiscoverX

P07: Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors, Presented by Daniel B., Eurofins DiscoverX

P08: SPRINTer™ Platform: Detection of Endogenous Protein Turnover Induced by Targeted Degraders, Presented by Chao-Tsung Y., Eurofins DiscoverX

P09: Integrated Cardiac Proarrhythmic Risk Assessment Using Human-Induced Pluoripotent Stem Cell (hiPSC)-Derived Cardiomyocytes, Presented by Verena A., Eurofins Discovery

P10: Expanding the Toolbox of E3scan Ligand Binding Assay Platform for Targeted Protein Degradation, Presented by Ksenya CK., Eurofins Discovery

P11: Generating Selective Hits for PIM3 Kinase Inhibitors, Example of a Comprehensive Screening Cascade, Presented by Poonam K., Eurofins Discovery

P12: Each New Target and Biology Merit a "One does not fit all" Solution, Presented by Maria G-P., Fairjourney Biologics

P13: Protein Characterization in 3D: Size, Folding and Functional Assessment in a Unified Approach, Presented by Henrik J., Fida Biosystems ApS

P14: Nucleoside Based-Drug Discovery and Development of FutureMedicine: Anti-Fibrotic/Anti-Inflammatory Diseases, Immune/Target Therapy In Tumor, Anti-Virus, Autoimmune, Presented by SangYeop A., Future Medicine

P15: Combining Targeting and Avidity for Stroma-Preferred Antagonism of the TGF-Beta Pathway, Presented by Travis B., Genentech

P16: Metabolic, Biochemical, Histopathological, and Transcriptomic Effects of Semaglutide and Lanifibranor Treatment in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH, Presented by Michael F., Gubra

P17: Isolation of Target-Specific Antibodies by Deep Mining the Antibody Repertoire of Immunized OmniChicken® by DeepDisplay™, Presented by Timothy M., ImmunoPrecise Antibodies Ltd.

P18: Successful Rabbit mAb CDR-Grafting: The First Step Towards Clinically Suitable Monoclonal Antibodies, Presented by Nick U., ImmunoPrecise Antibodies Ltd.

P19: RP6557, a Novel and Selective PI3K Delta/Gamma Inhibitor, Demonstrates Efficacy in Preclinical Models of Pulmonary Fibrosis, Presented by Satyam E., Incozen Therapeutics Pvt. Ltd.

P20: Expanding the Druggable Human Genome, Presented by Warren R., Iowa State University

P21: Synthetically-Derived PD-1 Antagonising VHHs Bind in Monomer and Multimer Formats to PD-L1-Expressing Breast Cancer Cells, Presented by Marion C., Isogenica Ltd.

P22: Novel Clinical Candidate JNC-1043 for TNBC Therapy, Presented by Jong-Ryoo C., J&C Sciences, Co., Ltd.

P23: New Antibiotic Resistance Enzymes of Bacteriophages, Providing Novel Targets for Drug Discovery, Presented by Sang Hee L., Myongji University

P24: SARS-CoV-2 Structural Analyses in Virtual Reality, Presented by Daniel G., Nanome, Inc.

P25: Structure-Based Design of Small Macrocyclic CDK9 Degraders as Chemical Biology Tools and Beyond, Presented by Carol G., Oncodesign SA

P26: Animal Models for Novel Therapies on Fibrosis and NASH: Pharmacological Validation and Gender Differences, Presented by Carol G., Oncodesign SA

P27: Identifying Novel Cancer Targets Using OneThree Biotech’s End-to-End AI Drug Discovery Pipeline, Presented by Brad P., OneThree Biotech

P28: Targeted Degradation of Endogenously Tagged Proteins for Phenotypic Studies Using HaloPROTAC3 and HaloTag Technologies, Presented by Steven E., Promega Corporation

P29: “Where” and “What” Off-Target Assessments Using Tissue Cross-Reactivity (TCR) and Retrogenix Cell Microarray Technologies, Presented by Nick B., Retrogenix, A Charles River Company

P30: Identifying Specific Cell Surface Heterodimer Receptors and Off-Targets: Integrin and CD3 Receptor Examples, Presented by Brad G., Retrogenix, A Charles River Company

P31: Two-Way Applicability Domain for Drug-Kinase Binding Affinity Prediction Problem, Presented by Davor O., Ruder Boskovic Institute

P32: An AI-Based Comprehensive Platform for Novel Target Identification, Presented by Hee Jung K., Standigm, Inc.

P33: Tools to Facilitate Antibody Discovery in Mice: Upstream Immunomagnetic Isolation of Antibody-Secreting Cells and Expansion of Primary B Cells In Vitro, Presented by Trevor R., STEMCELL Technologies, Inc.

P34: Profiling CEACAM7 as a Potential Target for Pancreatic Cancer, Presented by Sonali D., Syngene International Ltd.

P35: Predicting Trigenic Interactions for Cancer Therapeutic Multi-Targeting, Presented by Susan M., Systems Oncology LLC

P36: Discovery of Slack Potassium Channel Inhibitor Tool Compounds: Hit Optimization of VU0531245, Presented by Alshaima'a Q., University of North Texas Health Science Center

P37: Ligand Recognition in G Protein-Coupled Receptor: A Quantum Chemical Analysis, Presented by Pawan B., University of Toledo

P38: Systematic Process for Patient Stratification: Identification of a TBK1-Driven Gene Signature in Anti-TNFα Non-RespondersPresented by Simone B., Takeda Pharmaceuticals, Inc.

P39: Blood-Based Signatures of Alzheimer's and Parkinson's Disease Observed Through Ubiquitin Proteasome System, Presented by Karteek K., LifeSensors, Inc.

P40: Mind the Gap: Ubiquitination and Targeted Degradation of ProteinsPresented by Patrick G., LifeSensors, Inc.